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The lymphatic system that extends throughout the whole body is one of useful targets for
efficient drug delivery. The intestinal lymphatic drug delivery has been actively studied to
date because administered drugs can avoid the first-pass metabolism in the liver, resulting
in improvement of oral bioavailability. Drugs must be hydrophobic in order to be trans-
ported into the intestinal lymphatics because the lipid absorption mechanism in the in-
testine is involved in the lymphatic delivery. Therefore, various lipid-based drug carrier
systems have been recently utilized to increase the transport of drug into the intestinal
lymphatics. Lipidic molecules of the lipid-based drug delivery systems stimulate produc-
tion of chylomicrons in the enterocytes, resulting in an increase in drug transport into
lymphatic in the enterocytes. This review summarizes recently reported information on
development of liposomal carriers for the intestinal lymphatic delivery and covers
important determinants for successful lymphatic delivery.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction drug delivery systems suitable for the targeting of drug to theLymphatic drug delivery is receiving increasing attention
because of its many advantages over other routes. This
attention has included a number of trials evaluating transport
of drug to the lymphatic system. Various lipid-based nano-
carriers have been developed to selectively utilize the
lymphatic system for drug delivery. In this review, we will
summarize recent advances in developing novel liposomal82 10 9872 3384 (mobile)
this work.
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The lymphatic system is a drainage network that extends
throughout the entire body in proximity to the circulatory; fax: þ86 2 816 7338.
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sugar, oxygen and lymphocytes that have leaked into the
interstitial space, to the blood. The intestinal lymphatic sys-
tem also contributes to the absorption of products from lipid
digestion such as long chain fatty acids and lipophilic vita-
mins. In addition, the lymphatic system transports various
immune cells and other elements essential to immune system
function.
From the point of view of drug delivery, the lymphatic
system is a very attractive target since orally administered
drugs can work more effectively when transported selectively
to the intestinal lymphatic system. Various drugs that are
absorbed from the intestine into the systemic circulation have
poor oral bioavailability due to degradation of active drug in
the gastrointestinal tract prior to absorption. The pH of
stomach fluidmay range from 1.0 in the fasted state to 3.0e4.0
in the fed state and this extremely acidic environment facili-
tates the degradation of orally administered drugs. Moreover,
before entering the systemic circulation, drug absorbed into
the portal venous system undergoes first-pass metabolism in
the liver. This results in a lower bioavailability and plasma
concentration of the drug.
On the other hand, highly lipophilic drugs that have a log
P> 5 and a long-chain triglyceride (TG) solubility>50mg/gwill
transit across the enterocyte and associate with enterocyte
lipoproteins to form chylomicrons [1]. These chylomicrons
and the associated drugs then enter the mesenteric lymph
duct, move to the thoracic duct, and finally enter the systemic
circulation at the junction of the left jugular and the left
subclavian veins. As a result of this anatomy, highly lipophilic
drugs can avoid hepatic first pass metabolism.Fig. 1 e A mechanistic model of the absorption pathway of dru
phospholipids from liposomes are utilized to stimulate product
the 2-MG pathway on smooth ER. Drug associated with CM is ex
modified from reference [2].The bioavailability of drugs that undergo significant first-
pass metabolism in the liver can be improved by utilizing
the lymphatic system for absorption in the intestine, thus
avoiding the first-pass effect in the liver. Additionally, toxicity
profiles of drugs can be changed since drug concentration and
persistence in the lymphatic system and systemic circulation
will be influenced by the dynamics of intestinal lymphatic
transport [2].
Furthermore, the lymphatic system can be a target for
treatment of other diseases such as acquired immune defi-
ciency syndrome (AIDS) and cancer. Human immunodefi-
ciency virus (HIV), which causes AIDS, colonizes lymphoid
organs such as the spleen, thymus and lymph nodes. In the
early stage of infection and throughout the latent stage, the
virus replicates vigorously in lymphoid organs, meaning that
lymphatic drug delivery can be advantageous in the treatment
of AIDS [3]. The lymphatic system also contributes to metas-
tasis of certain cancers. Because lymphatic vessels have pores
for entry and exit of immune cells, tumor cells can easily enter
the vessels and move to distant organs resulting in metas-
tasis. Therefore, if chemotherapeutic drugs can be targeted to
the lymphatic system it may be possible to inhibit the
metastasis of solid tumors [4e7].
To transport drugs to the lymphatic system via the intes-
tine, specific physiological conditions should be established.
That is, lymphatic drug delivery depends on the physiological
processes of lipid digestion and absorption. The lipid digestion
and absorption process associated with the lymphatic de-
livery of lipophilic drugs has been extensively reviewed
[8e10]. For example, in the case of the lipophilic antimalarial
drug halofantrine (log P 8.5, TG solubility >50 mg/ml), theg-encapsulated liposomes via intestinal lymphatics. Free
ion of chylomicrons by the G3P pathway on rough ER, and
pected to enter intestinal lymphatics. This figure has been
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the TG content of the lymph [11]. This suggests that lipid
digestion products are needed to stimulate the production of
chylomicrons. Thus, several types of lipid-based nano-
particles can be employed to mimic the physiological condi-
tions favorable for lymphatic drug delivery.
2.1. Lipid-based nanoparticles as intestinal lymphatic
drug delivery systems
As shown in Fig. 1, the co-administration of drug with a lipid-
based formulation stimulates enterocyte production of chy-
lomicrons, which dissolve and load lipophilic drugs in their
nonpolar core and thereby promote absorption into the in-
testinal lymphatics and organs. Therefore, lipophilic drugs are
absorbed into the intestinal lymph by association with lymph
lipoproteins [12,13].
Nanocarriers can be used to overcome many of the draw-
backs of conventional dosage forms; their use might help to
improve solubility and dissolution rate, increase bioavail-
ability, protect sensitive drugs from degradation, and reduce
side effects. Furthermore, this type of nanoparticle formula-
tion raises the possibility of targeting specific biological sites
either passively or actively. Unique features of nanocarriers
such as size and lipophilicity can be taken advantage of to
target drugs to specific tissues or organs like the liver or the
brain. We can also deliver drugs to other specific sites or
cellular targets by modifying their surfaces [14]. There exist
several types of lipid-based nanoparticles we can use for this
purpose (Table 1). As an informative figure, the structural
drawing of lipid-based nanoparticles such as multilayer lipo-
some, solid lipid nanoparticle, and self-microemulsifying drug
delivery system can be seen in Fig. 2.
2.1.1. Solid lipid nanoparticles
Solid lipid nanoparticles (SLNs) are lipid-based drug carriers
that remain solid at room and body temperatures. Lipids uti-
lized for SLNs are typically physiological lipids, including:
fatty acids, steroids, waxes and mono-, di-, or triglyceride
mixtures. SLNs are composed of a lipid core that stimulates
formation of chylomicrons, which transport the carrier and
associated drugvia the classical transcellular mechanism of
lipid absorption [12]. This process increases the absorption of
drugs into the lymphatic system. SLNs also have the potential
to allow: controlled drug release and drug targeting, increasedTable 1 e Lipid-based drug delivery systems studied for lymph
Delivery systems Drug name
SLNs Clozapine BA from SLN >
Tobramycin BA from SLN >
SMEDDS Halofantrine Lymphatic ava
Raloxifene Intestinal pen
Vinpocetine BA from SMED
Liposomes Cefotaxime BA from liposo
(þ)-catechin BA from elasti
Cyclosporin A BA from liposo
Calcitonin BA from carbo
rhEGF BA from PEG-cdrug stability and high drug payload. They can be produced
and sterilized in large quantities, can be used to deliver both
lipophilic and hydrophilic drugs, and lack the biotoxicity of
organic solvents. Additionally, SLNs are being used increas-
ingly for the protection of labile drugs from degradation in the
body and for sustained release [15,16].
Clozapine SLNs administered intravenously and intra-
duodenally showed increased bioavailability with an increase
in (AUC) of 3 and 4.5 times, respectively, as compared to clo-
zapine suspension. This increased AUC for SLNs could be due
to avoidance of first pass hepatic metabolism by SLNs driven
intestinal lymphatic transport. The positively charged cloza-
pine SLNs showed increased bioavailability with an increase
in AUC as compared to neutral charged clozapine SLN. This
may be because positively charged particles are better taken
up by intestinal lymphatics than neutral or negatively charged
particles. Increase in chain length of triglycerides was also
positively correlated with extent of lymphatic absorption of
the clozapine SLNs [17]. Tobramycin, a drug that is not
absorbed through the GI tract and is administered parenter-
ally, was administered to rats duodenallyin the form of SLNs
resulting in 100 and 20 times higher AUC than IV-
administered tobramycin SLNs and tobramycin solution,
respectively. This difference between the two administration
routes can be attributed to the transmucosal transport of SLN
to lymph instead to blood [18]. These results indicate that
SLNs could be a useful drug delivery system that improves the
bioavailability of lipophilic drugs.
2.1.2. Self-nanoemulsifying drug delivery systems
Self-emulsifying drug delivery systems (SEDDS) are mixtures
of natural or synthetic oils, solid or liquid surfactants, or
alternatively, one or more hydrophilic solvents and co-
solvents/surfactants used for the improvement of oral ab-
sorption of highly lipophilic drugs. Upon mild agitation
followed by dilution in aqueousmedia, such as GI fluids, these
systems can form fine oileinewater (o/w) emulsions or
microemulsions. Self-emulsifying formulations spread easily
in the GI tract, and the digestive motility of the stomach and
the intestine provide the agitation necessary for self-
emulsification. The oil represents one of the most critical ex-
cipients in the SEDDS formulation not only because it can
solubilize marked amounts of the lipophilic drug or facilitate
self-emulsification, but importantly because it can increase
the portion of lipophilic drug transported via the intestinalatic delivery.
Remark References
suspension [19]
solution [20]
ilability of 17.9% [20]
etration ability of SMEDDS > suspension [21]
DS > suspension [22]
mes > aqueous solution [24]
c liposome > conventional liposome [30]
me with bile salt > conventional liposome [33]
pol-coated liposome > noncoated liposome [35]
oated liposome > DPPC liposome [38]
Fig. 2 e A structural drawing of multilayer liposome (A), solid lipid nanoparticle (B), and emulsified oil droplet formed from
self-microemulsifying drug delivery system (C).
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the GI tract depending on the molecular nature of the tri-
glyceride emulsion [19].
Oral administration of halofantrine SMEDDS used for
treatment of malaria showed the lymphatic availability of
17.9% via the thoracic duct and produced a total bioavailability
of 74.9% [20]. The raloxifene SMEDDS exhibited improved
penetration ability compared to the plain drug suspension in
the in vitro intestinal permeability studies. SMEDDS formu-
lations of raloxifene are expected to improve the oral
bioavailability as evidenced by the increased penetration
ability of raloxifene SMEDDS. Although the exactmechanisms
responsible for this improved absorption are not fully identi-
fied, the reasons for the enhancement of bioavailability would
be stimulation of lymphatic transport due to the triglyceride
core of chylomicrons [21]. Comparing with vinpocetine (VIP)
crude drug powder and commercial tablets, negatively
charged VIP-SMEDDS exhibited 3.4- and 2.9-fold increase,
respectively, in the percent of accumulated dissolution at 3 h.
Relative bioavailability of negatively charged VIP-SMEDDS and
positively charged VIP-SMEDDS increased by 1.85- and 1.91-
fold, respectively, in relative of VIP crude powder suspen-
sion. The reasons for enhanced bioavailability of VIP would be
contribute to the improved release, enhanced lymphatic
transport, and increased penetration ability of VIP-SMEDDS
[22]. These results indicated that the S(M)EDDS is potentially
a good drug delivery system for oral delivery of the hydro-
phobic drugs.
2.1.3. Emulsion
Emulsions are heterogeneous delivery systems generally
consisting of a dispersed phase and a continuous phase with
the interface between them. In oil-in-water emulsions, the oil
is dispersed as dropletswithin an aqueous phase.Water-in-oil
emulsions are also possible. Emulsions with droplet sizes
<100 nm are called microemulsions and are thermodynami-
cally stable systems. Microemulsions are systems consisting
of water, oil, surfactants and cosurfactants, and they have the
capacity to solubilize both water-soluble and oil-soluble
drugs. Emulsions and microemulsions can be used as car-
riers for drugs with poor water solubility, as sustained-release
systems and as site-specific drug delivery vehicles by binding
ligands for various cell-receptors to the particle surface [14].
Administration of a poorly water-soluble drug as an
emulsion may improve bioavailability by eliminating a slowdissolution step as a barrier to drug absorption, by enhancing
intestinal lymphatic drug transport, or by a combination of
both processes. Other potential mechanisms by which emul-
sions may enhance drug absorption include effects on
gastrointestinal membrane permeability, transit time or on
the metabolism of the drug [23].
2.1.4. Liposomes
A liposome is a vesicle containing a lipid bilayer composed of
unimers that usually have a hydrophilic head and a hydro-
phobic tail and are oriented so that the hydrophobic head
groups are inside the bilayer. Among the lipid-based nano-
particular drug delivery systems potentially useful for effica-
cious lymphatic drug delivery, liposomes have received
significant attention for its ability to enhance the permeability
of drugs across the enterocyte, to stabilize drugs, and to pro-
vide the opportunity of controlled release [1]. For this reason,
more about liposomal carriers as lymphatic drug delivery
systems will further extensively discussed in the following
section of the review.3. Significance of liposomal carriers for
intestinal lymphatic drug delivery
3.1. Improvement of stability and bioavailability of drug
by liposomes
Liposomal drug carriers for oral administration were devel-
oped in the 1970s to protect labile drugs from denaturation by
the acidic environment of the digestive system. The use of
liposomal drug carriers resulted in decreased degradation
rates and increased uptake of drugs.
For example, cefotaxime, a hydrophilic drug with poor
bioavailability, was encapsulated in liposomal carriers to
protect it from the effects of low pH and increase transport of
the drug into the intestinal lymph as well as its systemic
bioavailability [24]. To evaluate drug-encapsulated liposomes
for oral delivery of drugs with poor bioavailability, the authors
compared three forms of the drug: a liposomal formulation,
aqueous free drug, and a mixture of the drug and empty li-
posomes. Oral bioavailability of the drug in the liposomal
formulation and drug given with empty liposomes was 2.7-
fold and 2.3-fold greater, respectively, than that of drug
given in aqueous solution. They also reported that lymphatic
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to the other formulations. Thus, liposomes can be used as
drug carriers to increase the intestinal lymphatic transport
and the oral bioavailability of hydrophilic drugs with poor
bioavailability.
Since DNA vaccines are unstable after oral administration,
an effective method is needed to improve their stability. Oral
delivery of liposomes with entrapped DNA vaccines was re-
ported by Perries et al. [25]. Their stability studies in simulated
intestinal media revealed significant differences in excreted
IgA levels between mice dosed with liposome-encapsulated
DNA and mice dosed with naked DNA. The immunological
response induced by liposomal DNA vaccines was bigger than
that induced by naked DNA. This result could be attributed to
the increased stability of distearoylphosphatidylcholine lipo-
somes in the gut, resulting in the protection of DNA from
nuclease, and to increased uptake by the gut lymphatic sys-
tem. These experiments suggest that employing liposomal
carriers for drugs given orally can increase DNA transport to
the lymphatic system.
3.2. Improvement of penetration ability of liposomes
across enterocytes
Encapsulation of drugs in liposomes alone cannot always
achieve increased lymphatic transport. The ability of lipo-
somes to penetrate biomembranes is important for lymphatic
drug delivery. The nanoparticles must be small and deform-
able enough to cross biomembranes [26e28]. There have thus
been several studies focused on the improvement of lipo-
somal penetration for oral lymphatic delivery.
Hashida et al. studied the in vivo absorption characteristics
of liposomes containing carboxyfluorescein as a model com-
pound. They compared the plasma and lymph concentration
of the released carboxyfluorescein to that of the free dye [29].
However, there was no significant difference between the
concentrations achieved with the two formulations, indi-
cating that the liposomes encapsulating the compound did
not sufficiently permeate the intestinal mucosa. To overcome
this limitation, they co-administrated lipid-surfactant mixed
micelles and the liposomal formulation. This resulted in
enhanced penetration of drug-containing liposomes by the
interaction between the lipid-surfactant micelle and the
bilayer of the intestinal cell membrane.
There was also a trial of elastic liposomes measuring
improvement of oral bioavailability of (þ)-catechin [30]. The
authors incorporated ethanol and a nonionic surfactant,
Tween 80, into liposomes to increase their flexibility. Ethanol
and Tween 80 influence the phosphatidylcholine bilayers of
liposomes by increasing the environmental heterogeneity of
phospholipids [26e28]. They also reported that incorporation
of the compounds into nano-sized liposomes can increase the
lipid surface area and consequently the bioavailability
compared to simple liposomes. The bioavailability of the
compound and the stability of the liposomes stored in simu-
lated GI fluids both improved with addition of Tween 80 and
ethanol.
Bile salt was also tested to see if it improved liposomal
penetration of biomembranes. Bile salt-stabilized vesicles
(bilosomes), which have shown potential in oral vaccinedelivery [31e33], may both protect antigens from the hostile
environment of the GI tract and improve transmucosal uptake
and immunization [32]. Bilosome-encapsulated cyclosporin A
(CyA) showed superior oral bioavailability due to enhanced
penetration of the bilosomes [34]. The CyA-encapsulated
bilosomes also promoted uptake by M-cells in Peyer’s
patches, and thereby increased absorption through the
lymphatic system. Furthermore, the incorporation of bile salts
into liposomes may stabilize the membrane against the
detrimental effects of physiological bile acids in the GI tract
[31].
3.3. Effect of liposomal surface charge on drug transport
across enterocytes
Liposomal surface charge has been experimentally modified
in attempts to increase drug transport to the intestinal
lymphatic system. The residence time of the liposomal drug
carrier in the GI tract influences drug bioavailability. In an
effort to increase the GI residence time of the liposomal drug
carrier, liposomal surface charge was modified by coating the
liposomeswith Carbopol and chitosan, thereby changing their
mucoadhesive properties [35]. Negatively-charged carbopol
(CP)- or positively-charged chitosan (CS)-coated liposomes
encapsulating calcitonin showed a 2-fold increase in phar-
macological efficacy over non-coated liposomes. The
mucoadhesive properties of the CP- and CS-coated liposomes
were measured by a particle counting method. The negatively
charged CP-coated liposomes and the CS-coated liposomes
had a higher adhesion percentage than positively charged li-
posomes, resulting in improved pharmacological efficacy [35].
In another trial investigating liposomal surface charge
modification, CyA-loaded liposomes prepared with cationic
stearylamine (SA), anionic phosphatidylserine (PS), and
coatedwith CSwere developed [36]. The authors evaluated the
mucoadhesivity of the liposomes. Mucoadhesive tests using
rat intestine showed that the best adhesion rate among the
three formulations belonged to liposomes prepared with SA
(liposomes prepared with PS: 56%, liposomes coated with CS:
61%). These results indicate that a positive surface charge on
liposomal drug carriers could enhance intestinal lymphatic
delivery.
Unilamellar dipalmitoylphosphatidylcholine (DPPC) lipo-
somes with a negative surface charge are another vehicle
developed for transport of antigens to stimulate an immune
response [37]. The authors demonstrated M-cell uptake and a
successful immune response in rats given these liposomes
with a negative surface charge.
3.4. Liposomes with coating material for enhanced
performance
Modified liposomes have been used to increase transport of
drugs to the intestinal lymphatics. For example, poly-
ethyleneglycol (PEG)-coated liposomes were developed to
improve absorption of human epidermal growth factor
(rhEGF), a single-chain polypeptide containing 53 amino acid
residues and three disulfide bonds [38]. Although liposomes
are useful carriers for intestinal lymphatic delivery of drugs,
they are vulnerable to digestion by bile salts [39e41]. To
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ethyleneglycol were created [39,40]. PEG-coated liposomes
containing rhEGF were shown to have the potential to
improve the GI stability and absorption of rhEGF [38]. The area
under the concentration time curve was increased 1.7- and
2.5-fold by both phosphatidylcholine and DPPC liposomes,
respectively. This increase in AUC is attributable to increased
resistance to enzyme degradation and improved penetration
of biological membranes.
Liposomes coated with proteins have also been produced.
For example, liposomes coated with the reovirus cell attach-
ment protein d1, a ligand for receptors existing on M cells,
were created [42]. These protein-coated liposomes had a 10-
fold greater degree of association with rat Payer’s patches
after in vitro incubation at 4 C for 1 h than did uncoated li-
posomes. This indicates that the protein-coated liposomes
selectively adhered to the M cells and were thereby trans-
ported into mucosal lymphoid tissue, resulting in an
enhanced immune response. This demonstrates the feasi-
bility of targeting orally administered antigen for delivery to
the lymphatic system via Peyer’s patches.
3.5. Drug-related factors affecting the use of liposomal
carriers
3.5.1. Physicochemical properties of drug candidates
The physicochemical properties of drugs critically influence
the efficacy of oral delivery to the lymphatic system because
these properties affect loading, or the concentration of drug
per chylomicron. The two properties regarded as most
important for loading of drug into chylomicrons are the
partition coefficient and the TG solubility.
Affinity between drugs and TG is very important for
lymphatic delivery. Charman et al. proposed that the partition
coefficient and TG solubility of drug candidates should be log
P > 5 and >50 mg/ml, respectively [1]. They compared
lymphatic transport of dichlorodiphenyltrichloroethane
(DDT) (log P 6.19) with hexachlorobenzene (HCB) (log P 6.53) to
dissect the importance of lipid solubility. Even though they
have similar log P values, 33.5% and 2.3% of the administered
dosage of DDT and HCB was transported to the lymphatic
system, respectively. This result was attributed to the 13-fold
difference in TG solubility between the two compounds [1].
However, the combination of a high partition coefficient
and a high TG solubility is not sufficient for lymphatic
delivery of drugs. In one trial, only 3% of administered
panclomedine, an antitumor agent with log P of 5.48 and a
TG solubility of 175 mg/ml, was transported to the intes-
tinal lymph [43]. Similarly, CI-976, a lipophilic lipid regu-
lator with a log P of 5.83 and a TG solubility of >100 mg/ml
showed very poor transport with <1% of the dose reaching
the intestinal lymph [44]. Furthermore, the authors re-
ported a high level of lymphatic delivery of halofantrine
hydrochloride HfeHCl (43.7% of the dose). This degree of
transport was similar to that of the lipophilic Hf presum-
ably because of conversion of HfeHCl to the lipophilic free
base in the intestinal lumen [45].
Taken in totality, this research suggests that a drug’s
partition coefficient and TG solubility are important de-
terminates of lymphatic transport. However, more research isneeded to establishwith certainty all the factors important for
successful lymphatic transport of drugs.
3.5.2. Prodrugs designed for enhanced lymphatic delivery
The lipophilicity of drugs can also be increased by attaching
lipid molecules. Various lipid molecules such as a fatty acids,
monoglycerides, diglycerides, or phosphoglycerides can be
covalently bound to drugs to produce prodrugs. This approach
is based on the fact that high lipophilicity is required for
transport into intestinal lymph. An early attempt to increase
the lipophilicity of drugs was a synthesis of simple esters by
condensation with long-chain fatty acids.
For example, therewas a trial to increase the bioavailability
of testosterone. The absolute bioavailability of unmodified
testosterone was approximately 4% due to first-pass hepatic
degradation [46]. An absolute bioavailability of about 7% was
achieved by attaching a lipid molecule to the hormone, pro-
ducing a lipophilic ester prodrug [47]. In another study, epi-
tiostanol, an anti-tumor agent, was modified by attaching 17-
methoxycyclopentane ether to the drug producing an ether
derivative of epitiostanol. The modified drug had superior
bioavailability when compared with native testosterone
[48e50].
This approach is limited by esterases and some peptidases
existing inmost organs of the body. Cleavage of ester bonds of
prodrugs may occur before the prodrugs are associated with
enterocyte-derived chylomicrons and arrest transit to the
lymphatic system. Other approaches have been tried to
overcome this limitation. As an advanced approach, prodrugs
can be integrated into a biochemical pathway related to lipid
processing. For example, glyceride-based prodrugs have been
synthesized for integration into the lymphatic triglyceride
absorption pathway [51e56].
GarzoneAburbeh et al. estimated the ability of diglyceride
prodrugs of L-dopa and chlorambucil to be integrated into
lymphatic triglyceride pathways [4,55]. L-Dopa is a drug that
undergoes significant first-pass metabolism in the liver
resulting in a low oral bioavailability. To transport this drug to
the intestinal lymph, they attached palmitic acid moieties in
the 1 -and 3-positions and L-Dopa in the 2-position of a glyc-
erol backbone. The 2-substituted L-Dopa derivative, which
was a 2-monoglyceridemimic, is absorbed and integrated into
the TG resynthesis pathway after the fatty acids covalently
bound in the 1- and 3-positions are cleaved. 8.3% of the
administered L-Dopa was present in lymph as the diglyceride
prodrug, while 0.2% of the dose of the original L-Dopa
administered orally was delivered to the intestinal lymphatic
system.
Inanother study of the prodrug approach, a phospholipid-
mimicking prodrug was produced. In the intestinal lumen
phospholipids are hydrolyzed to lyso-phospholipids that are
recycled after their absorption by enterocytes. Lymphatic de-
livery of fluorouridine, an anti-tumor agent, was attempted
using this pathway [56]. The authors produced dipalmitoyl-
phosphatidylfluorouridine (DPPF) as a phospholipid drug, and
then analyzed thoracic lymph after oral administration. The
concentration of DPPF-related congeners was approximately
30-fold larger than the plasma concentration of the prodrug,
confirming that the prodrug was specifically transported to
the intestinal lymph.
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drugs and lipid molecules, prodrugs can be a useful strategy
for increasing the drug dose transported to the intestinal
lymphatic system.4. Conclusion and future perspectives
Various lipid-based nanoparticles for oral lymphatic delivery
of drugs are increasingly being researched and developed.
Liposomes containing entrapped drug are particularly useful
nanocarriers that improve the oral bioavailability and efficacy
of drugs by selectively utilizing intestinal lymphatic absorp-
tion, thus evading first-pass hepatic metabolism.
However, more research is needed to elucidate the
mechanisms of selective transport of drugs to the intestinal
lymphatics by liposomes, specifically processes at the
cellular level including the digestion, uptake, and intracel-
lular metabolism of the phospholipid from liposomes and
drugs.
Moreover, the weaknesses of liposomes such as the sta-
bility of them in the stomach and the intestine also should be
overcome to develop more advanced drug delivery system for
the intestinal lymphatic delivery. Additionally, delivery of a
broader range of candidate drugs having different physico-
chemical characteristics such as hydrophilicity, hydropho-
bicity and instability in the GI tract must be tested. Further
study of liposomes for lymphatic delivery is required not only
to overcome these issues but also to develop more novel
liposomal drug delivery systems for future uses.
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